Escárcega Ricardo O, Baker Nevin C, Lipinski Michael J, Koifman Edward, Kiramijyan Sarkis, Magalhaes Marco A, Gai Jiaxiang, Torguson Rebecca, Satler Lowell F, Pichard Augusto D, Waksman Ron
Section of Interventional Cardiology, MedStar Heart and Vascular Institute, MedStar Washington Hospital Center, Washington, DC.
Section of Interventional Cardiology, MedStar Heart and Vascular Institute, MedStar Washington Hospital Center, Washington, DC.
Am Heart J. 2016 Mar;173:118-25. doi: 10.1016/j.ahj.2015.12.012. Epub 2015 Dec 29.
Transcatheter aortic valve replacement (TAVR) is the current standard for nonoperable and high-risk surgical patients with aortic stenosis, including those of advanced age. However, the clinical profiles, procedural characteristics, and outcomes of nonagenarians undergoing TAVR have not been thoroughly reported.
A total of 654 patients (n = 107 >90 years old and n = 547 <90 years) with severe aortic stenosis undergoing TAVR were included in this analysis. Baseline characteristics, procedural variables, and in-hospital outcomes and complications at 30 days and 12 months were analyzed.
Overall, of the patients included, 46% were high risk and 53% inoperable. Although nonagenarians had a higher Society of Thoracic Surgeons score of 9.2 ± 4 (12.1 ± 4 vs 8.6 ± 4, P < .001), other factors were considerably lower in this group: diabetes (22% vs 36%, P = .008), hyperlipidemia (65% vs 83%, P < .001), prior coronary artery bypass (13% vs 39%, P < .001), and mean body mass index (24.5 ± 5 vs 28.1 ± 7 kg/m(2), P < .001). The correlates for 1-year mortality in nonagenarians were as follows: ≥moderate aortic insufficiency post-TAVR (hazard ratio [HR] 5.07, 95% CI 1.17-22, P = .03), pacemaker implantation after TAVR (HR 6.87, 95% CI 2.32-20.3, P = .001), and peripheral vascular disease (HR 2.35, 95% CI 1.03-5.38, P = .042). Mortality at 30 days (12.1% vs 7.1%, P = .07) and at 1 year (25% vs 21%, P = .35) was similar between groups.
Nonagenarians undergoing TAVR had a healthier clinical profile compared with younger patients. Age alone should not be a discriminatory factor when screening elderly patients with aortic stenosis because even the nonagenarians are doing well when compared with the younger elderly population. Transcatheter aortic valve replacement remains a viable option for the treatment of severe symptomatic aortic stenosis for the elderly regardless of their age.
经导管主动脉瓣置换术(TAVR)是目前无法进行手术及手术风险高的主动脉瓣狭窄患者(包括高龄患者)的治疗标准。然而,关于90岁及以上老人接受TAVR的临床特征、手术特点及预后尚未有详尽报道。
本分析纳入了654例接受TAVR的严重主动脉瓣狭窄患者(年龄>90岁者107例,<90岁者547例)。分析了基线特征、手术变量以及30天和12个月时的院内结局及并发症。
总体而言,纳入患者中46%为高风险,53%无法进行手术。尽管90岁及以上老人的胸外科医师协会评分更高,为9.2±4(12.1±4 vs 8.6±4,P<.001),但该组其他因素显著更低:糖尿病(22% vs 36%,P=.008)、高脂血症(65% vs 83%,P<.001)、既往冠状动脉搭桥术(13% vs 39%,P<.001)以及平均体重指数(24.5±5 vs 28.1±7 kg/m²,P<.001)。90岁及以上老人1年死亡率相关因素如下:TAVR术后≥中度主动脉瓣关闭不全(风险比[HR]5.07,95%CI 1.17 - 22,P=.03)、TAVR术后起搏器植入(HR 6.87,95%CI 2.32 - 20.3,P=.001)以及外周血管疾病(HR 2.35,95%CI 1.03 - 5.38,P=.042)。两组30天死亡率(12.1% vs 7.1%,P=.07)和1年死亡率(25% vs 21%,P=.35)相似。
与年轻患者相比,接受TAVR的90岁及以上老人临床特征更健康。在筛查老年主动脉瓣狭窄患者时,不应仅以年龄作为区分因素,因为即使是90岁及以上老人与年轻老年人群相比效果也较好。经导管主动脉瓣置换术仍是治疗老年严重症状性主动脉瓣狭窄的可行选择,无论其年龄大小。